JANX Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 19.72%. Janux Therapeutics's return on equity of -11.37% beat Gilead Sciences's return on equity of 32.29%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 197.84%. On the other hand Gilead Sciences has an analysts' consensus of $116.85 which suggests that it could grow by 7.4%. Given that Janux Therapeutics has higher upside potential than Gilead Sciences, analysts believe Janux Therapeutics is more attractive than Gilead Sciences.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.290, suggesting its less volatile than the S&P 500 by 71.014%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.87% to investors and pays a quarterly dividend of $0.79 per share. Janux Therapeutics pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Janux Therapeutics's net income of -$23.5M is lower than Gilead Sciences's net income of $1.3B. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 22.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 121.07x versus 4.77x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Harrow has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -37.17%. Janux Therapeutics's return on equity of -11.37% beat Harrow's return on equity of -35.99%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 197.84%. On the other hand Harrow has an analysts' consensus of $59.40 which suggests that it could grow by 64.36%. Given that Janux Therapeutics has higher upside potential than Harrow, analysts believe Janux Therapeutics is more attractive than Harrow.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Harrow has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.3%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harrow offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Harrow pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Harrow quarterly revenues of $47.8M. Janux Therapeutics's net income of -$23.5M is lower than Harrow's net income of -$17.8M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Harrow's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 121.07x versus 6.07x for Harrow. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 23.32%. Janux Therapeutics's return on equity of -11.37% beat Johnson & Johnson's return on equity of 30.18%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 197.84%. On the other hand Johnson & Johnson has an analysts' consensus of $173.66 which suggests that it could grow by 6.55%. Given that Janux Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Janux Therapeutics is more attractive than Johnson & Johnson.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.08% to investors and pays a quarterly dividend of $1.30 per share. Janux Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. Janux Therapeutics's net income of -$23.5M is lower than Johnson & Johnson's net income of $5.5B. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 121.07x versus 4.36x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -6742.75%. Janux Therapeutics's return on equity of -11.37% beat Vir Biotechnology's return on equity of -45.02%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 197.84%. On the other hand Vir Biotechnology has an analysts' consensus of $17.63 which suggests that it could grow by 221.04%. Given that Vir Biotechnology has higher upside potential than Janux Therapeutics, analysts believe Vir Biotechnology is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vir Biotechnology has a beta of 1.224, suggesting its more volatile than the S&P 500 by 22.375%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Vir Biotechnology pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Vir Biotechnology quarterly revenues of $1.8M. Janux Therapeutics's net income of -$23.5M is higher than Vir Biotechnology's net income of -$121M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Vir Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 121.07x versus 52.51x for Vir Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.